Publique en esta revista
Información de la revista
Vol. 55. Núm. 7.
Páginas 393-394 (Julio 2019)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 55. Núm. 7.
Páginas 393-394 (Julio 2019)
Letter to the Editor
DOI: 10.1016/j.arbres.2019.01.027
Acceso a texto completo
Right Heart Catheterization Further Confirms Successful Transition from Parenteral Prostanoid to Oral Selexipag
El cateterismo cardíaco derecho confirma con éxito el cambio de prostanoides parenterales a selexipag vía oral
Visitas
169
María Lázaro Salvadora,
Autor para correspondencia
maria.lasal@gmail.com

Corresponding author.
, Pilar Escribano Subíasb, Luis Rodriguez Padiala
a Department of Cardiology, Hospital Virgen de la Salud, Toledo, Spain
b Department of Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Tablas (1)
Table 1. Risk profile assessment.
Texto completo
Dear Editor,

Pulmonary arterial hypertension (PAH) is a progressive pulmonary vasculopathy with devastating prognosis. Only three therapeutic targets (endothelin, nitric oxide, and prostacyclin) are currently available to slow down the progression of the disease. Parenteral prostacyclin analogues are recommended in patients suffering from severe PAH with high-risk profile.1 Treprostinil, a prostacyclin analogue, improves patients’ risk profile but frequently associates severe pain at infusion site. Oral selexipag is a novel orally available non-prostacyclin selective prostacyclin receptor (IP receptor) agonist,2 currently approved to treat intermediate risk PAH patients.

We recently reported the first successful switch from subcutaneous treprostinil to oral selexipag in a stable PAH patient reporting unbearable adverse events related to treprostinil subcutaneous administration.3 Six months after treprostinil withdrawal, the patient non-invasive risk profile had slightly improved and her quality of life drastically increased. At that time invasive data were lacking. We relied on non-invasive prognostic markers (WHO FC, NTproBNP and 6MWD),4 adding echocardiogram and cardiopulmonary exercise test parameters to increase accuracy.

There is still little experience with transition to oral selexipag from parenteral prostacyclin therapy,5 and further investigation is required to confirm safety and efficacy of this switch. Therefore, we communicate that one year has elapsed since our patient started transition to selexipag, and treprostinil was completely withdrawn more than 10 months ago. She maintains her previously achieved low risk profile,3 and finally accepted to undergo right heart catheterization. Low risk profile achievement is now documented also invasively, and with longer follow up (Table 1).

Table 1.

Risk profile assessment.

6MWD: 6minutes walking distance; CPET: cardiopulmonary Exercise Test; VO2: oxygen uptake; RA: right atrium; RAP: right atrial pressure; SvO2: mixed venous oxygen saturation; CI: cardiac index.

Colors are: Red for high risk, Yellow for intermediate risk, Green for low risk. These are taking from risk evaluation table proposed in ESC/ERS Guidelines published in 2016, and used current in clinical daily practice.

Taking into account that PAH is a progressive disease, the fact that the patient remains stable, in confirmed low risk profile, 10 months after withdrawal of parenteral prostanoids, highlights the safety of transition from parenteral prostanoids to oral selexipag in adequately selected patients.

References
[1]
N. Galie, M. Humbert, J.L. Vachiery, S. Gibbs, I. Lang, A. Torbicki, et al.
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
Eur Heart J, 37 (2016), pp. 67-119
[2]
Olivier Sitbon, Richard Channick, Kelly M. Chin, Aline Frey, Sean Gaine, Nazzareno Galiè, GRIPHON study, et al.
Selexipag for the treatment of pulmonary arterial hypertension.
N Engl J Med, 373 (2015), pp. 2522-2533
[3]
M. Lázaro Salvador, F. Akerström, P. Escribano Subías, A. Berenguel Senén, V. Martinez Mateo, L. Rodriguez Padial.
Living with severe pulmonary arterial hypertension without an infusion pump? Selexipag has a role to play.
[4]
A. Boucly, J. Weatherald, L. Savale, X. Jaïs, V. Cottin, G. Prevot, et al.
Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.
[5]
S.M. Fanous, M. Janmohamed.
Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: case series.
Am J Health Syst Pharm, 75 (2018), pp. 1877-1881
Copyright © 2019. SEPAR
Idiomas
Archivos de Bronconeumología

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.